Recruiting

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(10 sites)

United States

University of California, Los Angeles (Site #: 71123), Los Angeles, California

Johns Hopkins (Site #: 71119), Baltimore, Maryland

University of Minnesota (Site 71151), Minneapolis, Minnesota

Washington University (Site #: 71157), St Louis, Missouri

NYU Langone Health (Site #: 71177), New York, New York

Duke University (Site #: 71139), Durham, North Carolina

Cincinnati Children's Hospital Medical Center (Site #: 71017), Cincinnati, Ohio

Cleveland Clinic (Site #: 71101), Cleveland, Ohio

University of Pennsylvania (Site #: 71111), Philadelphia, Pennsylvania

Vanderbilt University Medical Center (Site #: 71174), Nashville, Tennessee